prasterone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
androgens/anabolic steroids 795 53-43-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • intrarosa
  • 5,6-didehydroepiandrosterone
  • androstenolone
  • dehydroandrosterone
  • dehydroepiandrosterone
  • dehydroisoandrosterone
  • prasterone
A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
  • Molecular weight: 288.43
  • Formula: C19H28O2
  • CLOGP: 3.07
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 37.30
  • ALOGS: -3.82
  • ROTB: 0

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
6.50 mg V

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 190.06 65.94 53 101 73545 2284386
Butterfly rash 84.45 65.94 11 143 205 2357726
Periorbital oedema 67.40 65.94 11 143 1007 2356924

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC A14AA07 ALIMENTARY TRACT AND METABOLISM
ANABOLIC AGENTS FOR SYSTEMIC USE
ANABOLIC STEROIDS
Androstan derivatives
ATC G03EA03 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION
Androgens and estrogens
ATC G03XX01 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Other sex hormones and modulators of the genital system
MeSH PA D000276 Adjuvants, Immunologic
MeSH PA D007155 Immunologic Factors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Systemic lupus erythematosus indication 55464009 DOID:9074
Dyspareunia indication 71315007

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
6.5MG INTRAROSA AMAG PHARMS INC N208470 Nov. 16, 2016 RX INSERT VAGINAL 8957054 Aug. 7, 2028 INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
6.5MG INTRAROSA AMAG PHARMS INC N208470 Nov. 16, 2016 RX INSERT VAGINAL Nov. 16, 2021 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sex hormone-binding globulin Secreted Kd 7.84 CHEMBL
Glucose-6-phosphate 1-dehydrogenase Enzyme Ki 5.21 CHEMBL
Corticosteroid-binding globulin Secreted Ki 5 CHEMBL
Glucose-6-phosphate 1-dehydrogenase Enzyme Ki 5.96 CHEMBL

External reference:

IDSource
D003687 MESH_DESCRIPTOR_UI
4021360 VUID
N0000148779 NUI
C0011185 UMLSCUI
D08409 KEGG_DRUG
459AG36T1B UNII
2869 INN_ID
413963008 SNOMEDCT_US
78316004 SNOMEDCT_US
4021360 VANDF
73034 MMSL
20676 MMSL
131731 MMSL
004609 NDDF
32118 MMSL
d04425 MMSL
4036745 VANDF
3143 RXNORM
CHEBI:28689 CHEBI
CHEMBL90593 ChEMBL_ID
DB01708 DRUGBANK_ID
2370 IUPHAR_LIGAND_ID
5881 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Prastera HUMAN PRESCRIPTION DRUG LABEL 2 55607-400 KIT 200 mg ORAL unapproved drug other 20 sections
Intrarosa HUMAN PRESCRIPTION DRUG LABEL 1 64011-601 INSERT 6.50 mg VAGINAL NDA 16 sections
Viatrexx-Mesenchyme HUMAN PRESCRIPTION DRUG LABEL 9 73069-102 INJECTION 31 [kp_C] INTRAVENOUS unapproved drug other 11 sections
Viatrexx-Male Plus HUMAN PRESCRIPTION DRUG LABEL 5 73069-320 INJECTION 201 [kp_C] INTRAVENOUS unapproved drug other 11 sections